Skip to main content
OpenTrials
Completed

NCT Number: NCT00777855

Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.

The purpose of this study is to determine the importance of uptake drug transporters in the drug disposition of warfarin. We predict that the elimination of warfarin will be decreased when co-dosed with an inhibitor of uptake drug transporters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UCSF Medical Center

San Francisco, California, 94112, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female 18-60 years of age;
  • Healthy adult with no active medical problems or significant chronic diseases as determined by the study doctor based on history, physical exam and laboratory evaluations;
  • BMI between 18.5 - 30 kg/m2;
  • Taking no medications 2 weeks before and during the study enrollment, including drugs of abuse, prescription or over-the-counter (OTC) medications (except acetaminophen);
  • Subjects able to maintain adequate birth control during the study independent of hormonal contraceptive use;
  • Be able to provide written informed consent and comply with requirements of the study;
  • Avoid eating grapefruit and drinking grapefruit juice from 7 days before the first study day until completion of the entire study;
  • Abstinence from alcoholic beverages, caffeinated beverages and orange juice from 6pm the night before a study day until completion of that study day;
  • Avoidance of contact sports and/or other activities with significant risk of trauma injury for 7 days after each study day.
  • Fast from food and beverages at least 8 hours prior to medication dosing;
  • Be able to read, speak and understand English

Exclusion criteria

  • Subjects on prescription or chronic over-the counter medications (including hormonal contraceptives);
  • Subjects with known allergy to warfarin and/or rifampin;
  • Subjects who are not homozygous for cytochrome P450 2C9 (CYP2C9 *1) (known poor metabolizers).
  • Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias;
  • Subjects with liver failure or liver function test (LFT) results >2x upper limit of normal;
  • Subjects with clinically significant elevations in international normalized ratio (INR), prothrombin (PT), prothrombin time (PTT), serum creatinine (SCr), blood urea nitrogen (BUN) or other screening laboratory tests as determined by study physician;
  • Subjects with Hct <30 mg/dL;
  • Subjects with history of GI bleed or peptic ulcer disease;
  • Subjects with a recent history of trauma;
  • Subjects with a recent history of or upcoming plan of surgery;
  • Subjects who smoke tobacco;
  • Subjects with ongoing alcohol or illegal drug use;
  • Subjects who are pregnant, lactating or attempting to conceive;
  • Subjects unable to maintain adequate birth control during the study;
  • Subjects unable to follow protocol instructions or protocol criteria.

Treatment and study plan

warfarin plus rifampin

Drug

warfarin 7.5mg po x 1; rifampin 600mg IV x 1

Warfarin

Drug

warfarin 7.5mg po x 1

Primary outcomes

  1. S- and R- Enantiomers of Warfarin (S-warfarin and R-warfarin) Area Under the Plasma Concentration-time Curve (AUC) From 0 to 12 Hours.

    Time frame: 0-12 hours after warfarin dosing

    Uptake effects on warfarin pharmacokinetics during time period of hepatic organic anion-transporting polypeptide (OATP) inhibition by rifampin. Blood collection 1, 2, 4, 6, 8, and 12 hours after warfarin dosing.

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity of S-warfarin and R-warfarin

    Time frame: 0-120 hours after warfarin dosing

    Analysis of all concentration-time data. Blood collection 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after warfarin dosing.

  2. Maximum Plasma Concentration (Cmax) of S-warfarin and R-warfarin

    Time frame: 0-120 hours after warfarin dosing

    Blood collection 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after warfarin dosing.

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Official study title

The Effects of Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers.

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Oct 22, 2008
Registry last updated
Jul 17, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.